Impact on the paradigm of preventing exacerbations of chronic obstructive pulmonary disease
https://doi.org/10.25694/URMJ.2018.10.39
Abstract
Chronic obstructive pulmonary disease (COPD) has a varying frequency and severity of exacer-bations. The fixed combination of tiotropium / olodaterol (TIO/OLO) demonstrate a reduction of risk moderate and severe exacerbations compare to tiotropium (TIO) in patients with COPD. Ti-otropium-olodaterol reduced the rate of exacerbations treated with systemic corticosteroids (SCS) alone, and reduced the rate of exacerbations treated with SCS and antibiotics compared with tiotropium.. There was no difference in the number of adverse events including major ad - verse cardiac events between TIO/OLO and tiotropium groups.
About the Authors
I. V. Leshchenko
ФГБОУ ВО Уральский государственный медицинский университет МЗ РФ; ООО «Медицинское объединение «Новая больница»
Russian Federation
Russian Federation
V. N. Antonov
ФГБОУ ВО Южно-Уральский государственный медицинский университет МЗ РФ
Russian Federation
Russian Federation
E. V. Blinova
ФГБОУ ВО Южно-Уральский государственный медицинский университет МЗ РФ
Russian Federation
Russian Federation
G. L. Ignatova
ФГБОУ ВО Южно-Уральский государственный медицинский университет МЗ РФ
Russian Federation
Russian Federation
E. A. Medvedskyi
ООО «Медицинское объединение «Новая больница»
Russian Federation
Russian Federation
N. M. Trifanova
ООО «Медицинское объединение «Новая больница»
Russian Federation
Russian Federation
References
1. Seemungal T.A., Donaldson G.C., Bhowmik A. et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 161: 1608 - 1613.
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI /WHO workshop report. Last updated 2018.www.goldcopd.org
3. Hurst J.R., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363: 1128 - 1138.
4. Soler-Cataluna JJ, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005; 60: 925 - 931.
5. Wedzicha J.A., Seemungal T.A. COPD exacerbations: defining their cause and prevention. Lancet 2007; 370: 786 - 796.
6. Miravitlles M., D'Urzo A., Singh D., Koblizek V Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review. Respiratory Research 2016; 17: 112.
7. Miravitlles M., Calle M., Soler - Cataluna J.J. Clinical phenotypes of COPD: identification, definition and implications for guidelines. Arch. Bronconeumol 2012; 48: 86 - 98.
8. Айсанов З.Р., Авдеев С.Н., Архипов В.В. и др. Национальные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких: алгоритм принятия клинических решений. Пульмонология. 2017; 27(1): 13 - 20.
9. Calverley P.M., Anzueto A.R., Carter K. et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel - group, active - controlled trial. Lancet Respir Med 2018; doi: 10.1016/ S2213 - 2600(18)30102 - 4.
10. Calverley P.M.A., Anzueto A.R., Dusser D. et.al. Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD. Inter. J. COPD 2018; 13: 1297 - 1308.
11. Wedzicha J.A., Calverley P.M., Seemungal T.A. et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177: 19 - 26.
12. Авдеев С.Н., Белевский А.С., Айсанов З.Р. и др. Возможности ингаляционной терапии по предупреждению обострений ХОБЛ. Заключение Совета экспертов Российского респираторного общества. Пульмонология 2018; 3: 368 - 380.
Review
For citations:
Leshchenko IV, Antonov VN, Blinova EV, Ignatova GL, Medvedskyi EA, Trifanova NM. Impact on the paradigm of preventing exacerbations of chronic obstructive pulmonary disease. Ural Medical Journal. 2018;(10):106-109. (In Russ.) https://doi.org/10.25694/URMJ.2018.10.39
Views:
121
Email this article 